| 영문 | complement | 한글 | 보체 |
|---|---|---|---|
| 설명 | 항체와 반응하여 항체와 결합된 세포의 파괴를 일으키는 단백질을 말한다. 항체가 항체와 결합한 세포를 파괴하는 방법에는 여러 가지가 있는데 그 중의 하나로 항체와 결합한 세포의 표면을 부분적으로 손상시켜 그 세포를 파괴하는 역할을 하는 것이 이 보체이다. 보체는 20가지의 단백질로 구성되어 있는데 약자로 C로 표시하며 각 종류를 나타낼 경우에는 C옆에 숫자를 써서 표시한다. |
||
| 영문 | complement fixation reaction | 한글 | 보체결합 반응, 도움체결합반응 |
|---|---|---|---|
| 설명 | 항체와의 반응에 있어서 보체와 결합하는 항체를 검사하는 방법으로, 이 반응은 최초에 기지항원, 피검혈청 및 보체를 혼합한다. 제2단계에서는 적혈구와 이것에 대응하는 용혈소의 혼합액을 가한다. 본 반응후 용혈이 일어나지 않으면 본체는 항원항체결합물에 결합한 것이 되어 양성이 되지만, 용혈이 일어난 경우 보체는 결합하지 않아 소비되지 않기 때문에 음성이 된다. 본 반응은 기지혈청을 써서 항원검출에 응용할 수 있으며, 마이코플라스마, 리케챠, 클라미디아, 바이러스, 매독 등의 진단에 쓰인다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
| C3 | Complement factor 3 |
|---|---|
| ACP | Alternative complement pathway |
| C | Complement |
| C' 3 | Complement |
| C3 | Complement 3 |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| complement factor I | <enzyme> Serine proteinase that acts on ic3b (inactivated complement 3b) to cleave it into c3c and c3dg with the help of a trypsin-like proteolytic enzyme. Complement factor I was formerly called kaf, c3binf, or enzyme 3b inactivator. Registry number: EC 3.4.21.45 (12 Dec 1998) |
|---|
| complement 3 nephritic factor | A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b. (12 Dec 1998) |
|---|---|
| complement chemotactic factor | The activated complex of the fifth, sixth, and seventh components of complement (C567) which induces chemotaxis in the case of polymorphonuclear leukocytes. (05 Mar 2000) |
| complement factor h | <chemical> A beta-globulin that binds to complement 3b and makes ic3b (inactivated complement 3b) susceptible to cleavage by complement factor I. Complement factor h also acts as an alternative pathway complement inhibitor by interfering with the binding of properdin factor b to c3b. Chemical name: Complement factor H (12 Dec 1998) |
| thyrotoxic complement-fixation factor | A form of thyrotoxin; an antigen found most readily in thyroid tissue from thyrotoxic individuals; known to be chemically and immunologically distinct from thyroglobulin, and fixes complement when combined with antibody related to the gamma-globulin fraction of serum. With the exception of extremely small concentrations, the antigen is rarely found in normal glands or in diseased glands that are not associated with thyrotoxicosis; it is probably an intracellular substance (possibly a constituent of the "microsomal fraction"), and does not contain iodine in significant quantity. Not related to the complement-fixation reaction occurring with serum in Hashimoto's disease, in which the antigen is thyroglobulin. (05 Mar 2000) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
| complement 1q | <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors. Chemical name: Complement C1q (12 Dec 1998) |
| complement 1r | <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage. Registry number: EC 3.4.21.41 (12 Dec 1998) |
Synonyms : C3b Inactivator, C3b-C4b Inactivator, C4b-C3b-INA, C4bC3bINA, Complement 3b-Complement 4b Inactivator, Complement C4b-C3b Inactivator, C3b C4b Inactivator, C4b C3b INA, C4b-C3b Inactivator, Complement, Complement 3b Complement 4b Inactivator, Inactivator, C3b
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|